Credit Suisse Group Downgrades Santen Pharmaceutical (OTCMKTS:SNPHY) to Neutral

Santen Pharmaceutical (OTCMKTS:SNPHY) was downgraded by equities research analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a report issued on Monday, The Fly reports.

Santen Pharmaceutical stock opened at $18.42 on Monday. Santen Pharmaceutical has a 1 year low of $13.00 and a 1 year high of $20.18. The business has a 50-day moving average of $18.29 and a 200-day moving average of $17.90.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-126 that is in Phase 2b clinical trial; DE-128, which is in Phase 2/3 clinical trial; DE-130A that is in Phase III clinical trial; and DE-117.

Further Reading: What is the LIBOR?

The Fly

Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.